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Castleman  disease  (CD)  is  a  rare  lymphoproliferative  disorder  of  unknown  etiology  with  different  clinical 
manifestations.  A  previous  healthy  50  year-old  man  was  hospitalized  for  right  upper  quadrant  (RUQ)  abdominal  pain. 
He  had  jaundice  and  a  1  cm-sized  lymph  node  in  the  right  supraclavicular  area.  Pancreas  and  biliary  computed 
tomography  (CT)  showed  masses  at  the  right  renal  hilum  and  peripancreatic  areas.  Positron  emission  tomography 
(PET)  showed  widespread  systemic  lymphadenopathy.  Excisional  biopsy  of  the  right  supraclavicular  node  revealed  a 
hyaline  vascular  variant  of  CD.  Corticosteroid  therapy  was  started  and  the  extent  of  disease  decreased.  We  here  report 
a  case  of  multicentric  CD,  the  hyaline  vascular  variant,  presenting  with  jaundice,  diagnosed  by  excisional  biopsy  and 
successfully  treated  with  corticosteroids.
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INTRODUCTION
Castleman  disease  (CD)  is  a  rare  lymphoproliferative  disorder. 
Clinical  features  of  the  disease  vary  from  asymptomatic  to 
symptomatic  lymphadenopathy  accompanied  by  fever,  malaise 
and/or  weight  loss.  Based  on  the  histological  findings  CD  is 
divided  into  two  variants  the  hyaline  vascular  variant  (HVV)  and 
the  plasma  cell  variant  (PCV).  When  disease  location  is 
considered,  CD  can  be  divided  further  into  three  types  including 
a  unicentric  HVV  found  in  72%  of  cases,  unicentric  PCV 
accounting  for  18%  of  cases  and  multicentric  PCV  identified  in 
10%.  The  following  case  has  two  unique  features:  (1) 
presentation  as  an  obstructive  jaundice  mimicking  acute 
cholangitis  and  (2)  presentation  as  a  widespread  systemic 
lymphadenopathy.  The  final  diagnosis  was  confirmed  as 
multicentric  HVV,  which  is  a  very  rare  variant  accounting  for 
only  1%  of  all  CD  cases. 
CASE REPORT
A  previously  healthy  50  year-old  male  patient  visited  the 
emergency  department  for  right  upper  quadrant  abdominal  pain. 
He  had  a  smoking  history  of  20  pack-years  and  quit  smoking 
seven  years  ago.  He  had  no  history  of  liver  disease  or  other 
illness  except  prurigo  simplex  and  papular  urticaria  on  both 
lower  extremities.  Three  weeks  prior  to  presentation,  he  visited 
a  local  clinic  for  loss  of  appetite  and  weight  loss  (4  kg/3 
months).  Gastrofibroscopy  and  colonoscopy  findings  were 
normal.  One  week  prior  to  presentation,  the  patient  began  to 
have  RUQ  discomfort,  which  progressed  to  pain  in  three  days. 
Physical  findings  were  normal  except  for  a  yellowish  skin  color 
and  a  1  cm-sized  lymph  node  at  the  right  supraclavicular  area. 
Initial  laboratory  testing  showed:  total  bilirubin  6.0  mg/dL,  ALP 
280  IU/L,  AST/ALT  125/248  IU/L,  gamma-GT  195  IU/L,  lipase 
1648  U/L  (23～300),  and  amylase  140  U/L  (60～180).  The 
Figure  1.  (A)  Contrast-enhanced  CT  scan  shows  a  homogeneous  mass  (arrow)  infiltrating  the 
right  renal  sinus.  This  mass  does  not  result  in  vascular  occlusion  or  hydronephrosis.  (B) 
Another  homogeneously  enhancing  soft  tissue  mass  (dotted  arrow)  is  noted  in  the 
peripancreatic  area. 
Figure  2.  FDG  PET  images  were  obtained  60  min  after  intravenous  injection  of 
370  MBq  of  [18F]-FDG  using  an  Allegro  PET  scanner  (Philips  Medical  System, 
Cleveland,  OH.,  USA).  2.5  minutes  emission  scans,  with  the  nine-table  position, 
from  the  level  of  the  proximal  femur  to  the  cerebellum  obtained  using  the  3D 
acquisition  mode.  An  attenuation  map  obtained  using  a  Cs-137  transmission 
source.  Attenuation  correction  images  reconstructed  using  a  3D-RAMLA  algorithm 
with a 3D image filter. (A-D) Coronal PET images show [18F]FDG-avid hyperplastic 
lymph nodes at bilateral cervical areas, mediastinum, hilar area, mid abdomen, and 
renal  hilar  area.  (E～H)  Transaxial  PET  images  co-registered  with  enhanced  CT. 
Arrows  indicate  FDG  accumulation  at  the  renal  hilar  lesion  (arrow)  and  the 
pancreatic  body  (dotted  arrow) 
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Figure  3.  (A)  Concentric  layers  of  small  lymphocytes  seen  around  the  reactive  germinal  centers  (original  magnification  ×200; 
hematoxylin-eosin stain). (B) A lymphoid follicle with a partially involved germinal center is transfixed by a penetrating arteriole. Concentric 
layers  of  small  uniform  lymphocytes  result  in  an  'onion-skin'  appearance  (original  magnification  ×400;  hematoxylin-eosin  stain).  (C)  Blood 
vessels  between  the  follicles  are  lined  by  hyperplastic  endothelial  cells  and  surrounded  by  fibrocollagen  (original  magnification  ×400; 
hematoxylin-eosin  stain).
 
Figure  4.  After  steroid  treatment,  contrast-enhanced  CT  scans  reveal  decrease  in  the  size  of  the 
masses  at  the  right  renal  sinus  (arrow)  and  the  peripancreatic  area  (dotted  arrow).
complete  blood  cell  count  (CBC)  was  normal  except  for  a 
slightly  increased  eosinophil  count  (668/μL).  Serum  antinuclear 
antibody,  rheumatoid  factor  and  anti-HIV  antibodies  were  all 
negative.  Pancreas  and  biliary  CT  showed  masses  at  the  right 
renal  hilum  and  the  peripancreatic  area  (Figure  1). 
Percutaneous  needle  biopsy  (PCNB)  from  the  renal  hilum 
revealed  a  patchy  infiltration  of  atypical  lymphoplasma  cells. 
However,  lack  of  sufficient  tissue  limited  an  accurate  diagnosis. 
Evaluation  for  additional  lymphadenopathy  with  whole  body  PET 
was  done.  It  revealed  multiple  positive  uptakes  in  the  cervical, 
right  hilar,  subcarinal,  and  subaortic  lymph  nodes  as  well  as  in 
the  peripancreatic  area  (Figure  2).  Additional  neck  and  chest  CT 
showed  multiple  enlarged  homogeneously  enhancing  lymph 
nodes  on  both  side  of  neck  and  mediastinum.  Excisional  biopsy 
of  the  right  supraclavicular  node  revealed  a  hyaline  vascular 
variant  of  CD  (Figure  3).  Immunohistochemical  findings  were 
CD20  (+),  CD3  (+),  CD21  (+),  CD10  (+  in  germinal  center),  bcl-2 
(+  in  paracortical  area),  and  HHV-8(-).  HHV-8  PCR  from 
peripheral  blood  mononuclear  cells  was  also  negative. 
After  the  administration  of  high  dose  corticosteroids  (1  mg/kg 
ABC
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of  prednisolone),  liver  function  improved  with  the  level  of  total 
bilirubin  decreasing  from  16.3  to  2.1  mg/dL,  ALP  from  348  to 
110  IU/dL  and  AST/ALT  from  291/1054  to  29/122  IU/L.  After  two 
weeks  of  treatment,  follow-up  abdominal  CT  showed  that 
pancreatic  swelling,  the  pararenal  mass  and  the  multiple 
peripancreatic  lymph  nodes  decreased  in  size  (Figure  4). 
DISCUSSION
Castleman  disease  is  rare,  and  its  scarcity  has  precluded 
comprehensive  studies  leading  to  an  incomplete  understanding 
of  its  pathophysiology
1).  Recent  reports  suggest  that  HHV-8 
infection  stimulates  B  lymphocytes  to  induce  lL-6  production  in 
the  mantle  zone
2-4).  The  proportion  of  HHV-8  infected  cases 
among  CD  patients  is  variable  and  reported  to  be  from  33%  to 
100%.  In  HIV-positive  patients,  nearly  all  CD  cases  have  been 
positive  for  HHV-8
5).  In  our  case,  immunohistochemical  staining 
of  lymph  nodes  and  peripheral  blood  PCR  revealed  no 
correlation  between  HHV-8  infection  and  the  disease.  Other 
exogenous  or  endogenous  factors  may  induce  IL-6  secretion 
from  B  lymphocytes  in  HHV-8  negative  CD.  Local  production  of 
IL-6  may  contribute  to  the  characteristic  B-cell  proliferation  and 
vascularization  observed  in  CD
6).  Moreover,  in  patients  with 
multicentric  CD,  systemic  symptoms  might  result  from  the 
circulation  of  IL-6  and  IL-6-producing  B  lymphocytes
7). 
In  order  to  diagnose  CD,  exclusion  of  other  diseases  with 
lymphadenopathy  is  very  important.  These  include  rheumatoid 
arthritis,  lupus,  Sjogren  syndrome,  HIV  infection,  lymphoma,  and 
drug  sensitivity.  For  our  patient  we  initially  thought  he  had 
lymphoma  causing  an  obstructive  jaundice  and  rapid 
deterioration.  There  were  no  specific  symptoms,  signs  or  history 
suggestive  of  inflammation,  infection  or  drug  sensitivity.  We 
used  the  PCNB  of  the  perirenal  mass  as  a  diagnostic  tool 
initially  in  order  to  start  chemotherapy  immediately.  Since  we 
failed  to  get  enough  tissue  from  the  PCNB  of  the  perirenal 
mass,  we  next  tried  an  excisional  biopsy  of  the  cervical  node. 
There  are  three  different  presentations  for  CD.  The  most 
common  type  is  the  unicentric  hyaline  vascular  variant  (U-HVV) 
accounting  for  72%  of  all  CDs.  A  single  node  or  a  chain  of 
lymph  nodes  is  involved  in  the  U-HVV  variant,  and  its  most 
common  location  is  the  mediastinum.  The  unicentric  plasma  cell 
variant  (U-PCV)  accounts  for  18%  of  all  cases  of  CD;  most 
U-PCV  patients  have  constitutional  symptoms  such  as  anemia, 
elevated  ESR  and  frequently  abdominal  lymph  nodes.  The  final 
type  is  the  multicentric  plasma  cell  variant  (M-PCV)  representing 
10%  of  all  CDs.  The  M-PCV  patients  are  usually  older  than  in 
the  other  variants  commonly  in  the  fifth  to  sixth  decade  of  life. 
Patients  with  M-PCV  frequently  present  with  fever, 
organomegaly  and/or  abnormal  laboratory  findings  such  as 
anemia  or  thrombocytopenia
9). 
Our  case  presented  with  an  abdominal  mass  and  systemic 
lymphadenopathy.  The  histological  type  was  confirmed  HVV. 
Neither  fever  nor  organomegaly  were  present  in  this  patient. 
The  only  symptoms  noted  on  presentation  were  those 
commonly  associated  with  an  obstructive  jaundice,  anorexia 
and/or  weight  loss.  The  proportion  of  patients  with  muticentric 
CD  and  HVV  is  less  than  1%  of  all  CD.  Soulier  J  reported  four 
patients  with  HVV  among  31  patients  with  multicentric  CD
10). 
Two  of  these  patients  had  systemic  symptoms  and  signs  and 
one  patient  had  HIV  infection  and  Kaposi's  sarcoma.  Two 
patients  were  male  and  three  patients  were  positive  for  HHV-8 
by  PCR. 
We  could  find  only  two  prior  reported  cases  of  CD  with 
obstructive  jaundice
11, 12).  A  filiform  stricture  of  the  common 
hepatic  duct  was  noted  in  the  first  case.  Laparotomy  confirmed 
U-HVV  involving  the  bile  ducts,  liver  parenchyma  and  adjacent 
lymph  nodes.  The  second  case  presented  with  enlarged  lymph 
nodes  in  the  porta  hepatis  and  the  common  bile  duct.  This  case 
was  confirmed  as  the  HVV  variant  of  CD  by  laparotomy. 
The  therapeutic  approach  to  multicentric  CD  depends  on 
whether  HHV-8  PCR  and  CD20  are  positive.  In  HHV-8 
PCR-positive  cases,  use  of  valgancilovir  is  considered.  For  the 
CD20-positive  cases,  treatment  is  with  rituximab  an  anti-CD20 
monoclonal  antibody
5).  Patients  presenting  with  both  markers 
negative  receive  treatment  with  immunosuppressive  agents  such 
as  prednisolone,  interferon-alpha,  thalidomide,  or  CHOP 
chemotherapy.  Our  patient  was  HHV-8  negative  and  CD20 
positive.  The  use  of  prednisolone  resulted  in  an  immediate 
decrease  in  the  size  of  the  mass  and  improved  laboratory 
profiles.  Follow  up  evaluations  of  symptoms,  laboratory  tests 
including  liver  function  and  image  studies  at  regular  intervals  are 
planned  for  this  patient. 
In  conclusion,  we  present  a  case  of  multicentric  CD 
presenting  with  jaundice.  PET  identified  widespread  systemic 
lymphadenopathy;  the  final  diagnosis  was  confirmed  as  CD,  the 
hyaline  vascular  variant. 
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